The Biomanufacturing Viral Detection and Quantification Market Size is valued at 466.52 Million in 2022 and is predicted to reach 981.41 Million by the year 2031 at a 8.8% CAGR during the forecast period for 2023-2031.
Viral clearance is necessary during the downstream purification of therapeutic biologics, blood, and tissue-derived materials. Viruses are either removed or inactivated for manufacturing microbiologically stable goods.
Reliable and fast viral detection and quantification techniques are required to advance basic research and clinical approaches. The biomanufacturing viral detection and quantification market is estimated to be driven by technological advancements in the viral testing domain and the increasing demand for biopharmaceutical products.
Due to the increasing utilization of biopharmaceuticals, the biomanufacturing viral detection and quantification market is growing rapidly. Quality control systems are essential to ensure biopharmaceuticals' safety, efficacy and consistency. This increases the demand for consumables and equipment for the identification & quantification of viral contaminants in the biomanufacturing process of biological products, thereby promoting the growth of the biomanufacturing viral detection and quantification market.
Competitive Landscape:
Some of the Key Players in the Biomanufacturing Viral Detection and Quantification Market:
- Danaher Corporation
- Merck KGaA
- New England Biolabs
- TAKARA HOLDINGS INC.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Sartorius AG
- Charles River Laboratories
- Bio-Rad Laboratories, Inc.
- PerkinElmer, Inc.
- Promega Corporation
- QIAGEN N.V.
- Genscript Biotech Corporation
- Norgen Biotek Corp.
- Other Prominent Players
Market Segmentation:
The Biomanufacturing Viral Detection and Quantification Market is segmented based on offering type, technology, application, and end user. The offering type segment includes consumables, instruments, and services. By technology, the market is bifurcated into PCR, ELISA, flow cytometry, plaque assay, and others. By application, the market is categorized into blood and blood products manufacturing, vaccines and therapeutics manufacturing, cellular and gene therapy products manufacturing, stem cell products manufacturing, and tissue and tissue products manufacturing. Based on end user, the market is divided into life science companies, testing laboratories, CROs and CDMOs.
The Consumables Segment Is Expected To Drive The Biomanufacturing Viral Detection And Quantification Market In The Upcoming Years
Based on offering type, the consumables segment dominated the biomanufacturing viral detection and quantification market in 2022. The surging adoption of kits, assays, monitoring and additional equipment has led to a significant increase in the consumables segment. Consumables are products and materials that are continuously used throughout the viral detection and quantification process. Many consumables are used in viral testing to determine the quantity or concentration of a particular virus in biological samples.
The PCR Technology Segment Is Expected To Grow At The Highest Rate
By Technology, PCR Technology Segment is expected to grow at the highest rate in the biomanufacturing viral detection and quantification market during the forecast period.
Virus detection and testing using polymerase chain reaction (PCR) technology has the advantage of high sensitivity and reproducibility. PCR testing can identify the development of the infection, monitor the response to treatment, and distinguish latent from active infection. Also, in virus monitoring, PCR assays help identify false positive results caused by inadvertent contamination of samples with traces of viral nucleic acids or PCR products.
Blood and Blood Products Manufacturing Segment Led The Market
Based on application, the biomanufacturing viral detection and quantification market was led by the blood and blood products manufacturing segment in 2022. Viral testing identifies and measures viral nucleic acids in blood samples and helps maintain the safety and quality of blood & blood products.
Life Science Companies dominate the biomanufacturing viral detection and quantification market
In terms of end users, the life science companies segment dominated the biomanufacturing viral detection and quantification market in 2022.
Maintaining quality control measures in the life sciences industries is crucial to manufacturing products with high safety, quality and efficiency. Viral detection and quantification methods are used at the drug/therapy development, production, and testing stages.
Regionally, North America led the Biomanufacturing Viral Detection and Quantification Market in 2022
North America held the largest share of the biomanufacturing viral detection and quantification market in 2022 and is predicted to continue its trend over the forecast period, owing to the presence of most key players, increased demand for cell & gene therapies, advancements in viral detection and quantification technologies. Furthermore, the Asia Pacific market is expected to accelerate over the projected period (2023-2031), owing to the continuous R&D efforts in the viral detection and quantification industry, the high utilization of biopharmaceutical products, and the rising funding for innovative therapy research.
Biomanufacturing Viral Detection and Quantification Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 466.52 Million |
|
Revenue Forecast In 2031 |
USD 981.41 Million |
|
Growth Rate CAGR |
CAGR of 8.8 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Offering Type, Technology, Application, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Danaher Corporation, Merck KGaA, New England Biolabs, TAKARA HOLDINGS INC., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Genscript Biotech Corporation, Norgen Biotek Corp., and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
